Cargando…
A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice
Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne virus that causes severe hemorrhagic fever disease in humans. Currently, no licensed CCHF vaccines exist, and the protective epitopes remain unclear. Previously, we tested a DNA vaccine expressing the M-segment glycoprotein precursor gene...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925670/ https://www.ncbi.nlm.nih.gov/pubmed/33654101 http://dx.doi.org/10.1038/s41541-021-00293-9 |
_version_ | 1783659320550883328 |
---|---|
author | Suschak, John J. Golden, Joseph W. Fitzpatrick, Collin J. Shoemaker, Charles J. Badger, Catherine V. Schmaljohn, Connie S. Garrison, Aura R. |
author_facet | Suschak, John J. Golden, Joseph W. Fitzpatrick, Collin J. Shoemaker, Charles J. Badger, Catherine V. Schmaljohn, Connie S. Garrison, Aura R. |
author_sort | Suschak, John J. |
collection | PubMed |
description | Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne virus that causes severe hemorrhagic fever disease in humans. Currently, no licensed CCHF vaccines exist, and the protective epitopes remain unclear. Previously, we tested a DNA vaccine expressing the M-segment glycoprotein precursor gene of the laboratory CCHFV strain IbAr 10200 (CCHFV-M(10200)). CCHFV-M(10200) provided >60% protection against homologous CCHFV-IbAr 10200 challenge in mice. Here, we report that increasing the dose of CCHFV-M(10200) provides complete protection from homologous CCHFV challenge in mice, and significant (80%) protection from challenge with the clinically relevant heterologous strain CCHFV-Afg09-2990. We also report complete protection from CCHFV-Afg09-2990 challenge following vaccination with a CCHFV-Afg09-2990 M-segment DNA vaccine (CCHFV-M(Afg09)). Finally, we show that the non-structural M-segment protein, GP38, influences CCHF vaccine immunogenicity and provides significant protection from homologous CCHFV challenge. Our results demonstrate that M-segment DNA vaccines elicit protective CCHF immunity and further illustrate the immunorelevance of GP38. |
format | Online Article Text |
id | pubmed-7925670 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-79256702021-03-19 A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice Suschak, John J. Golden, Joseph W. Fitzpatrick, Collin J. Shoemaker, Charles J. Badger, Catherine V. Schmaljohn, Connie S. Garrison, Aura R. NPJ Vaccines Article Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne virus that causes severe hemorrhagic fever disease in humans. Currently, no licensed CCHF vaccines exist, and the protective epitopes remain unclear. Previously, we tested a DNA vaccine expressing the M-segment glycoprotein precursor gene of the laboratory CCHFV strain IbAr 10200 (CCHFV-M(10200)). CCHFV-M(10200) provided >60% protection against homologous CCHFV-IbAr 10200 challenge in mice. Here, we report that increasing the dose of CCHFV-M(10200) provides complete protection from homologous CCHFV challenge in mice, and significant (80%) protection from challenge with the clinically relevant heterologous strain CCHFV-Afg09-2990. We also report complete protection from CCHFV-Afg09-2990 challenge following vaccination with a CCHFV-Afg09-2990 M-segment DNA vaccine (CCHFV-M(Afg09)). Finally, we show that the non-structural M-segment protein, GP38, influences CCHF vaccine immunogenicity and provides significant protection from homologous CCHFV challenge. Our results demonstrate that M-segment DNA vaccines elicit protective CCHF immunity and further illustrate the immunorelevance of GP38. Nature Publishing Group UK 2021-03-02 /pmc/articles/PMC7925670/ /pubmed/33654101 http://dx.doi.org/10.1038/s41541-021-00293-9 Text en © This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Suschak, John J. Golden, Joseph W. Fitzpatrick, Collin J. Shoemaker, Charles J. Badger, Catherine V. Schmaljohn, Connie S. Garrison, Aura R. A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice |
title | A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice |
title_full | A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice |
title_fullStr | A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice |
title_full_unstemmed | A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice |
title_short | A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice |
title_sort | cchfv dna vaccine protects against heterologous challenge and establishes gp38 as immunorelevant in mice |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925670/ https://www.ncbi.nlm.nih.gov/pubmed/33654101 http://dx.doi.org/10.1038/s41541-021-00293-9 |
work_keys_str_mv | AT suschakjohnj acchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice AT goldenjosephw acchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice AT fitzpatrickcollinj acchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice AT shoemakercharlesj acchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice AT badgercatherinev acchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice AT schmaljohnconnies acchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice AT garrisonaurar acchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice AT suschakjohnj cchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice AT goldenjosephw cchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice AT fitzpatrickcollinj cchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice AT shoemakercharlesj cchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice AT badgercatherinev cchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice AT schmaljohnconnies cchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice AT garrisonaurar cchfvdnavaccineprotectsagainstheterologouschallengeandestablishesgp38asimmunorelevantinmice |